Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Vigencell Inc. (308080:KRX), powered by AI.
Vigencell Inc. is currently trading at ₩7,390. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Vigencell Inc. on Alpha Lenz.
Vigencell Inc.'s P/E ratio is -10.1.
“Vigencell Inc. trades at a P/E of -10.1 (undervalued) with modest ROE of -21.7%.”
Ask for details →Vigencell Inc. is a biotechnology company that focuses on developing advanced cell-based therapies for the treatment of various cancers and autoimmune diseases. By utilizing innovative biotechnological techniques, Vigencell aims to enhance the body's immune response to target and eliminate malignant cells. The company emphasizes the research and development of personalized medicine, striving to create treatments tailored to the genetic profile of individual patients. Operating in the critical field of healthcare innovation, Vigencell impacts both the biotechnology and pharmaceutical sectors, contributing to the future of medicinal therapies with a focus on precision oncology. Founded with a commitment to addressing unmet medical needs, Vigencell collaborates with academic institutions and clinical research organizations to advance its therapeutic pipeline. The company’s initiatives are crucial in advancing medical treatments, offering new hope for patients with challenging conditions. As a player in the biotechnology field, Vigencell remains significant in the market for its potential to revolutionize how complex diseases are managed and treated.
“Vigencell Inc. trades at a P/E of -10.1 (undervalued) with modest ROE of -21.7%.”
Ask for details →Vigencell Inc. (ticker: 308080) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 64 employees. Market cap is $151.5B.
The current price is ₩7,390 with a P/E ratio of -10.11x and P/B of 2.45x.
ROE is -21.70% and operating margin is -5495.85%. Annual revenue is $279M.